ObjectiveIndividuals with the same disease causing variant of cystic fibrosis (CF) can have very different clinical outcomes, suggesting that yet‐to‐be identified modifier genes may play an important role in clinical presentation and disease progression. The epithelial sodium channel (ENaC) plays an important role in the pathophysiology of CF. Previous research has shown that substitution of alanine for threonine at position 663 of the SCNNA1 gene, which encodes the alpha subunit of ENaC, results in channel gain‐of‐function. In this study we sought to examine how genetic variation in the SCNNA1 gene influences clinical outcomes in CF.MethodsBuccal swabs were collected from thirty‐five CF patients that had at least one copy of the del.F508 mutation (19 males, 16 females). Samples were analyzed for allelic status at position 663 of SCNNA1 (AA, AT/TT). Medical charts were reviewed for resting vitals, pulmonary function, and indicators of disease progression.ResultsTwenty‐one subjects were homozygous for the alanine allele (AA, A663), 12 were heterozygous (AT) and 2 were homozygous for the threonine allele (TT). Due to low numbers in the TT group the AT and TT groups were combined for analysis (T663). Individuals in the T663 group had significantly higher resting heart rate (88±9 v 77±9, p=0.004) and tended to have lower body weight (133.7±56.5lbs v 143.6±31.9lbs), and higher systolic blood pressure (121±16.9mmHg v 115±16.5mmHg) compared to the A663 group. Forced vital capacity was significantly lower in the T663 group (3.64±1.12L v 4.29±0.94L, p=0.038). However FEV1/FVC was higher in the T663 group (75.0±12.1% v 71.8±11.0%, p=0.043), suggesting smaller lung volumes but not greater obstructive lung disease compared to the A663 group. There was no statistically significant difference in the frequency of pancreatic insufficiency or cystic fibrosis related type‐I diabetes between the two groups.ConclusionWe found that CF patients with the T663 allele tended to have smaller lungs as well as higher resting heart rate and blood pressure when compared to the A663 group. This finding suggests that the T663 variant results in cardiovascular compensation for altered pulmonary function.Support or Funding InformationNoneThis abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.